Oculis Alternatives & Competitors
12 companies similar to Oculis — Visionary Innovation
Companies similar to Oculis
Clearside Biomedical, Inc.
Revolutionizing the delivery of therapies to the back of the eye through the suprachoroida...
Novaliq GmbH
Transforming Ocular Therapeutics
Vantage Biosciences
Transforming diabetic eye disease with an oral treatment
FimmCyte
First disease modifying treatment for Endometriosis.
Rival Readout
Competing with Oculis? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Sling Therapeutics
Focused on late-stage development of an oral small molecule for the treatment of thyroid e...
Odyssey Therapeutics
Building a machine learning-based platform to develop novel therapeutics focusing on cance...
iCare
Establishing the next level of eye care.
ROME Therapeutics
Harnessing the power of the repeatome to develop a new class of therapies for cancer and a...
Yaqrit
The Liver Disease Company
Phyteau, Inc.
Designed by Nature, Delivered by Science: A new class of incretin therapy for diabetes, ob...
Emmaus Life Sciences, Inc
Improving the lives of people with rare disease.
Novoron Bioscience
Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the...
About Oculis
Oculis, founded in 2017, is a global biopharmaceutical company, publicly listed as Nasdaq: OCS and XICE: OCS. With headquarters in Switzerland and operations in the U.S. and Iceland, the company is focused on saving sight and enhancing eye care worldwide.
Development of ophthalmic and neuro-ophthalmic treatments, Innovative pipeline and clinical trials, Transformative patient-centric solutions
Patients with diabetic macular edema, Patients with dry eye disease, Patients with optic neuritis, Medical professionals in ophthalmology and neuro-ophthalmology
Biopharmaceutical Company, Ophthalmic Diseases, Drug Delivery Platform, Diabetic Macular Edema, Cataract Surgery Inflammation, Dry Eye Disease, Anterior Uveitis, Acute Optic Neuritis, Topical Eye Drops, Neuroprotection, Anti-TNFα Biologics, Non-invasive Treatments, Innovative Product Pipeline, Ophthalmology Innovation, International Healthcare Investors
B2B, B2C, B2D
Product Sales, Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Oculis: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Oculis on 6 May 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.